Article

Effect of cediranib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in a mouse model of choroidal neovascularization.

Department of Ophthalmology and Visual Science, College of Medicine, Clinical Research Institute, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea.
Clinical and Experimental Ophthalmology (Impact Factor: 1.96). 05/2012; DOI: 10.1111/j.1442-9071.2012.02813.x
Source: PubMed

ABSTRACT Background:  This study was conducted to evaluate the effect of cediranib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in a mouse model of laser-induced choroidal neovascularization (CNV). Methods:  CNV was induced in C57BL/6 mice by rupturing Bruch's membrane using laser photocoagulation. Following laser injury, the mice were divided into three groups and administered either vehicle, 1 mg/kg or 5 mg/kg of cediranib daily by oral gavage for two weeks. Two weeks after laser injury, the area of CNV lesions were measured by choroidal flat mounts using fluorescein-labeled dextran. Immunofluorescence staining with isolectin IB4 was also used to quantify the CNV lesions. Results:  Choroidal flat mount analysis revealed that orally administered cediranib reduced the extent of CNV. The groups treated with 1 and 5 mg/kg/day showed 57.2 and 66.0 % reduction of CNV lesions, respectively, compared to the control group treated with vehicle alone (P = 0.012). The size of the fluorescently labeled CNV complex in cediranib-treated groups was much smaller than that from vehicle-treated group (P = 0.035). Conclusions:  Cediranib inhibited laser-induced CNV in mice and may have therapeutic potential for patients with neovascular age-related macular degeneration. © 2012 The Authors. Clinical and Experimental Ophthalmology © 2012 Royal Australian and New Zealand College of Ophthalmologists.

0 Bookmarks
 · 
65 Views